Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Tags:  

BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:

About Abata Therapeutics

Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. Abata’s lead program is in progressive multiple sclerosis (MS), and its second program is in type 1 diabetes - both indications are tissue-specific autoimmune diseases with substantial unmet needs, supporting a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Watertown, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information.

---

---

Contacts

Media Cory Tromblee Scient PR cory@scientpr.com

Investor Julie Seidel Stern Investor Relations, Inc. julie.seidel@sternir.com

Media Cory Tromblee Scient PR cory@scientpr.com

Investor Julie Seidel Stern Investor Relations, Inc. julie.seidel@sternir.com